- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Clinical practice guideline for Sjögren’s syndrome 2017
-
- Takayuki Sumida
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Naoto Azuma
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Masafumi Moriyama
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Hiroyuki Takahashi
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Hiromitsu Asashima
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Fumika Honda
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Saori Abe
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Yuko Ono
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Tomoya Hirota
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
-
- Shintaro Hirata
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Yoshiya Tanaka
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Toshimasa Shimizu
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Hideki Nakamura
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Atsushi Kawakami
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Hajime Sano
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Yoko Ogawa
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Kazuo Tsubota
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Koufuchi Ryo
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Ichiro Saito
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Akihiko Tanaka
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Seiji Nakamura
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Etsuko Takamura
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Masao Tanaka
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Katsuya Suzuki
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Tsutomu Takeuchi
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Noriyuki Yamakawa
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Tsuneyo Mimori
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Akiko Ohta
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Susumu Nishiyama
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Toshio Yoshihara
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Yasunori Suzuki
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Mitsuhiro Kawano
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Minako Tomiita
- Clinical Practice Guideline Committee for Sjögren’s Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Tokyo, Japan;
-
- Hiroto Tsuboi
- Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan;
Search this article
Description
The objective of this study is to develop clinical practice guideline (CPG) for Sjögren's syndrome (SS) based on recently available clinical and therapeutic evidences.The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS.The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG.The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.
Journal
-
- Modern Rheumatology
-
Modern Rheumatology 28 (3), 383-408, 2018-03-13
Oxford University Press (OUP)
